Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA.
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Viruses. 2023 Nov 14;15(11):2255. doi: 10.3390/v15112255.
Integrase defective lentiviral vectors (IDLVs) are a promising vaccine delivery platform given their ability to induce high magnitude and durable antigen-specific immune responses. IDLVs based on the simian immunodeficiency virus (SIV) are significantly more efficient at transducing human and simian dendritic cells (DCs) compared to HIV-based vectors, resulting in a higher expansion of antigen-specific CD8+ T cells. Additionally, IDLV persistence and continuous antigen expression in muscle cells at the injection site contributes to the durability of the vaccine-induced immune responses. Here, to further optimize transgene expression levels in both DCs and muscle cells, we generated ten novel lentiviral vectors (LVs) expressing green fluorescent protein (GFP) under different hybrid promoters. Our data show that three of the tested hybrid promoters resulted in the highest transgene expression levels in mouse DCs, monkey DCs and monkey muscle cells. We then used the three LVs with the highest in vitro transgene expression levels to immunize BALB/c mice and observed high magnitude T cell responses at 3 months post-prime. Our study demonstrates that the choice of the vector promoter influences antigen expression levels in target cells and the ensuing magnitude of T cell responses in vivo.
整合酶缺陷型慢病毒载体(IDLVs)是一种很有前途的疫苗递送平台,因为它们能够诱导高强度和持久的抗原特异性免疫反应。与基于 HIV 的载体相比,基于猿猴免疫缺陷病毒(SIV)的 IDLV 能够更有效地转导人源和猿源树突状细胞(DCs),从而导致抗原特异性 CD8+T 细胞的更高扩增。此外,IDLV 在注射部位的肌肉细胞中的持续存在和持续抗原表达有助于疫苗诱导的免疫反应的持久性。在这里,为了进一步优化 DC 和肌肉细胞中转基因的表达水平,我们生成了十个表达绿色荧光蛋白(GFP)的新型慢病毒载体(LV),这些载体由不同的杂交启动子驱动。我们的数据表明,在测试的三个杂交启动子中,有三个在小鼠 DC、猴 DC 和猴肌肉细胞中产生了最高的转基因表达水平。然后,我们使用三种具有最高体外转基因表达水平的 LV 免疫 BALB/c 小鼠,并在首次免疫后 3 个月观察到高幅度的 T 细胞反应。我们的研究表明,载体启动子的选择影响靶细胞中的抗原表达水平以及体内 T 细胞反应的强度。
Mol Ther Methods Clin Dev. 2020-2-4
Expert Opin Biol Ther. 2011-3-25
Vaccines (Basel). 2025-5-15
Pharmaceutics. 2023-3-5
NPJ Vaccines. 2022-7-4
Expert Rev Vaccines. 2021-12
Viruses. 2021-8-2
Commun Biol. 2021-6-10